CrystalGenomics Completes Phase 1 Clinical Trial of Fibrosis Treatment 'CG-750'

[Asia Economy Reporter Oh Ju-yeon] CrystalGenomics announced on the 22nd that it has completed the Phase 1 clinical trial of the fibrosis treatment drug 'CG-750'.

This clinical trial was conducted at Seoul National University Hospital with 25 healthy adult males to compare and evaluate the safety and pharmacokinetics of the CG-750 capsule formulation and the CG-745 intravenous injection formulation.

The purpose of the trial was to compare and evaluate the bioavailability and safety of the oral formulation CG-750 against the intravenous injection formulation CG-745, thereby securing safety and pharmacokinetic evaluation data for the fibrosis treatment drug CG-750.

Through this, CrystalGenomics plans to officially begin developing CG-750 as a treatment for various fibrosis indications, including IPF (Idiopathic Pulmonary Fibrosis).

Additionally, the possibility of developing an oral formulation to improve medication convenience for the CG-745 intravenous injection formulation was also confirmed.

The company stated, "Through the development of an oral formulation, we expect to enhance patient convenience and reduce economic burden," adding, "Patients will be able to continue treatment through medication in daily life without having to visit the hospital each time." In contrast, the existing injection requires patients to visit the hospital for intravenous administration, which is inconvenient.

Meanwhile, fibrosis refers to the process of damaged tissue becoming fibrotic, with pulmonary and renal fibrosis being representative diseases. Recently, patients who have contracted COVID-19 are receiving treatment in Korea for pulmonary fibrosis as a sequela after recovery from COVID-19, making this disease even more noteworthy.

Going forward, the final clinical study report (CSR) of the single ascending dose (SAD) Phase 1 trial will be prepared and used as a basis for entering subsequent clinical trials.

A CrystalGenomics official said, "As fibrosis occurrence has been reported as a sequela of COVID-19 recently, expectations for the development of treatments are higher than ever."